Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer

Aparna Parikh, MD, leads a panel discussion surrounding updates and advancements in the metastatic colorectal cancer treatment landscape.

EP. 1: Overview of Current mCRC Treatment Landscape

February 22nd 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

EP. 2: Evaluating 3L Treatment Landscape Evolution

February 22nd 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

EP. 3: Fruquintinib MoA and Toxicity Profile Overview

February 29th 2024

Key safety considerations for the use of fruquintinib are explored.

EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

EP. 5: FRESCO-2 Study Highlights

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

EP. 8: Consideration for Fruquintinib Dosing and Titration

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

EP. 11: Considerations for Platinum-based Therapy

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

EP. 15: Unmet Needs Surrounding mCRC Treatment

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.